Inventor · disambiguated record
Hui-Qin Wang
Also filed as: WANG HUI · Wang hui-qin
3 granted patents·27 pending applications·1 citations·filing 2012–2024
53Inventor score
Top patents by PatentIndex Score
30 records- 0176US2025041310A1Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 InhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 0275US2025059293A1Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapyINCYTE CORP·Filed 2024·Application pending·0 cites
- 0372US10220038B2Pharmaceutical combinationsNOVARTIS AG·Filed 2018·Granted Mar 5, 2019·1 cites·9 claims
- 0471US2022280523A1Combination of pi3k inhibitor and c-met inhibitorNOVARTIS AG·Filed 2021·Application pending·0 cites
- 0568US2025114339A1Combination therapy comprising a kras g12d inhibitor and an egfr inhibitorINCYTE CORP·Filed 2024·Application pending·0 cites
- 0668US2025114346A1Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitorINCYTE CORP·Filed 2024·Application pending·0 cites
- 0763US2020253980A1Combination of pi3k inhibitor and c-met inhibitorNOVARTIS AG·Filed 2020·Application pending·0 cites
- 0862US12060433B2CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapyINCYTE CORP·Filed 2020·Granted Aug 13, 2024·0 cites·39 claims
- 0962US12053470B2Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitorNOVARTIS AG·Filed 2022·Granted Aug 6, 2024·0 cites·7 claims
- 1061US2021205311A1Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 InhibitorsINCYTE CORP·Filed 2020·Application pending·0 cites
- 1161US2015290204A1Combination therapyNOVARTIS AG·Filed 2013·Application pending·0 cites
- 1261US2019350935A1Combination of PI3K inhibitor and c-MET inhibitorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1360US2022281970A1Pharmaceutical CombinationsNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1459US2019083500A1Combination of PI3K Inhibitor and C-Met InhibitorNOVARTIS AG·Filed 2018·Application pending·0 cites
- 1558US2022233529A1Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodiesINCYTE CORP·Filed 2021·Application pending·0 cites
- 1658US2019160069A1Pharmaceutical combinationsNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1757US2023226040A1Combination therapy comprising an fgfr inhibitor and a kras inhibitorINCYTE CORP·Filed 2022·Application pending·0 cites
- 1855US2016331751A1Pharmaceutical compositionsFERRETTI STEPHANE·Filed 2014·Application pending·0 cites
- 1954US2018015092A1Pharmaceutical combinationsNOVARTIS AG·Filed 2017·Application pending·0 cites
- 2052US2016339023A1Pharmaceutical CombinationsLI FANG·Filed 2014·Application pending·0 cites
- 2152US2017143723A1Pharmaceutical combinationsNOVARTIS AG·Filed 2017·Application pending·0 cites
- 2251US2015216870A1Combination of PI3K Inhibitor and C-Met InhibitorCAPONIGRO GIORDANO·Filed 2013·Application pending·0 cites
- 2350US2019134033A1Pharmaceutical combinationsNOVARTIS AG·Filed 2018·Application pending·0 cites
- 2448US2017157134A1Combination therapyNOVARTIS AG·Filed 2017·Application pending·0 cites
- 2548US2018185365A1Pharmaceutical CombinationsNOVARTIS AG·Filed 2018·Application pending·0 cites
- 2644US2016287605A1Combination therapySHENG QING·Filed 2016·Application pending·0 cites
- 2744US2014275089A12-Carboxamide Cycloamino Urea Derivatives in Combination with HSP90 Inhibitors for the Treatment of Proliferative DiseasesNOVARTIS AG·Filed 2012·Application pending·0 cites
- 2843US2021363254A1Pharmaceutical combinationsNOVARTIS AG·Filed 2019·Application pending·0 cites
- 2942US2019343836A1Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitorNOVARTIS AG·Filed 2018·Application pending·0 cites
- 3037US2016199365A12-Carboxamide Cycloamino Urea Derivatives in Combination with HSP90 Inhibitors for the Treatment of Proliferative DiseasesHUANG XIZHONG·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Hui-Qin Wang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →